Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study.
Patients with mild to moderate essential hypertension (n = 1570) were enrolled in a large, multicentre, randomised, open-label study designed to evaluate the safety and efficacy of different regimens of carvedilol. Reported here are the effects of carvedilol on microalbuminuria (MAU) in a subset of 876 patients who underwent MAU assessment (i.e. the Micral-Test) at baseline and at week 12. MAU was present at baseline in 245 (28%) of these patients. Despite different magnitudes of blood pressure reduction, improvements in MAU were similar in all groups (range 54-60%), with complete disappearance occurring in 48-55% of patients. The decrease in MAU did not correlate with the magnitude of blood pressure reduction, suggesting a possible renal protective effect exerted by carvedilol independent of blood pressure reduction mediated by beta-blockade and vasodilatation.
Fassbinder
W
W
Städtisches Klinikum Fulda, Mannheim, Germany.
Quarder
O
O
Waltz
A
A
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000188:drug therapy*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002227:Carbazoles / Q000008:administration & dosage*; D000077261:Carvedilol; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007674:Kidney Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000008:administration & dosage*
D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol